论文部分内容阅读
研究我国制药企业的国际化经营,需要分析以下问题:1,哪一种研发方式最适合中国药企走国际化道路;2,哪一类新药、仿制药或中药是国际上急需的,其申报成功的决定因素和几率如何;3,中国医药走出国门的瓶颈在哪儿;4,如何克服中国医药企业通过国外GMP规定的暂时困难。本文通过对我国制药企业国际化的现状和存在问题的分析,并对照印度制药业发展的模式,提出了三个观点:从药品国际注册入手、积极探索国际并购、走联合研发模式。
To study the internationalization of pharmaceutical enterprises in China, we need to analyze the following questions: 1. Which research and development mode is most suitable for Chinese pharmaceutical enterprises to go international; 2. Which kind of new drugs, generic drugs or Chinese medicines are urgently needed in the world, 3) What is the bottleneck of Chinese medicine going abroad? 4) How to overcome the temporary difficulties that Chinese pharmaceutical companies have to pass the foreign GMP regulations? Based on the analysis of the status quo and existing problems of the internationalization of pharmaceutical companies in our country, and according to the development pattern of India’s pharmaceutical industry, this article puts forward three viewpoints: Starting from international registration of pharmaceutical products, actively exploring international mergers and acquisitions and taking joint R & D mode.